NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Recursion Pharmaceuticals and Exscientia announced a definitive agreement to combine and create a global technology-enabled drug discovery leader.
Recursion and Exscientia have entered into a definitive agreement to combine their businesses, aiming to create a leading technology-first, end-to-end drug discovery platform. The combined entity expects approximately 10 clinical readouts over the next 18 months and anticipates annual synergies of approximately $100 million.
- Recursion and Exscientia entered into a definitive agreement to create a global technology-enabled drug discovery leader with end-to-end capabilities.
- The combined business is positioned to leverage advances in life sciences and technology to deliver novel treatments to patients faster and at a lower cost.
- The combined pipeline has approximately 10 clinical readouts expected over the next 18 months.
- The combined company has a well-capitalized balance sheet with approximately $850 million in cash and cash equivalents as of the end of Q2 2024.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$14.4M
Revenue by segment
Recursion Pharmaceuticals · $1 total across 1 segment · Q2 2023
- Grant Revenue$1—100.0%
Forward guidance
The combined company anticipates significant advancements with potential milestone payments and revenue from partnerships, along with operational synergies and a strong cash runway.
Tailwinds
- Approximately 10 clinical readouts expected in the next 18 months.
- Potential for approximately $200 million in milestone payments over the next 2 years from current partnerships.
- Potential for more than $20 billion in revenue before royalties over the course of the partnerships.
- Estimated annual synergies of approximately $100 million.
- Cash runway extending into 2027.
Headwinds
- The transaction is subject to customary closing conditions, including approvals from shareholders, the High Court of Justice of England and Wales, and regulatory bodies.
- The integration of Exscientia’s business with Recursion’s business may face challenges.
- The combined company's operations, revenue, cash flow, and relationships with business partners could be affected by economic, market, or business conditions.
- There are risks associated with conducting business internationally.
- The market value of Recursion’s common stock to be issued in the proposed combination carries risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro